P&T
Our
Other
Journal
MediMedia Managed Markets

 

F. Randy Vogenberg RPh PhD's blog

F. Randy Vogenberg RPh PhD

Drug shortages might cause more drug substitutions which, in turn, could increase the chances of adverse events and the legal ramifications that go with them, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of Managed Care magazine’s Editorial Advisory Board. Newly created accountable care organizations need to be wary.

F. Randy Vogenberg RPh PhD

A health care consultant and member of Managed Care magazine’s Editorial Advisory Board says that under health reform, pharmacies will have a greater need to balance clinical and economic considerations. The less expensive drug might not always be preferable.

F. Randy Vogenberg RPh PhD

P&T committees will have to consider the economic fallout from their decisions as health reform advances, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of Managed Care magazine’s Editorial Advisory Board. That will be an adjustment.

F. Randy Vogenberg RPh PhD

Insurance coverage was never meant to handle new pharmaceutical breakthroughs on the radar — breakthroughs that can cost anywhere from $90,000 to $300,000 a year per patient, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of Managed Care magazine’s Editorial Advisory Board. There will be pressure on everybody to find a way to somehow control these costs.